Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403183 | 1.00 | PTK2B (0.58) | PTK2BSMN1; SMN2CDC25BACLYTDP1 | |
| SCHEMBL5030349 | 0.87 | PTK2B (0.44) | PTK2BSMN1; SMN2ACLYLMNAMAPK1 | |
| SCHEMBL940704 | 0.85 | PTK2B (0.43) | PTK2BSMN1; SMN2ACLYLMNATSHR | |
| SCHEMBL3160473 | 0.85 | LMNA (0.47) | PTK2BSMN1; SMN2CDC25BACLYTDP1 | |
| SCHEMBL11597913 | 0.84 | PTK2B (0.42) | PTK2BSMN1; SMN2RAB9ALMNAKMT2A | |
| SCHEMBL2593426 | 0.81 | PTK2B (0.58) | PTK2BSMN1; SMN2CDC25BACLYTDP1 | |
| SCHEMBL941191 | 0.81 | PKM (0.58) | PTK2BSMN1; SMN2CDC25BACLYTDP1 | |
| Hydrochloric Acid SCHEMBL11169517 | 0.80 | PKM (0.57) | PTK2BSMN1; SMN2CDC25BACLYTDP1 | |
| SCHEMBL19475371 | 0.80 | ACLY (0.51) | PTK2BSMN1; SMN2ACLYKMT2APKM | |
| SCHEMBL30695462 | 0.80 | ACLY (0.51) | PTK2BSMN1; SMN2ACLYKMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143091-A | HBV core protein degradation agent based on hydrophobic tag technology and preparation method and application thereof | 山东大学 | 2023-12-01 | — | — | CN | claimed |
| CN-113801153-A | Benzenesulfonyl amine HBV capsid protein inhibitor containing boric acid and boric acid pinacol ester group, and preparation method and application thereof | 山东大学 | 2021-12-17 | — | — | CN | claimed |
| EP-4698512-A1 | PROCESS FOR THE PREPARATION OF SULFAMOYLBENZOIC ACID DERIVATIVES | IAMA Therapeutics S.r.l. (IT) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2024218681-A1 | PROCESS FOR THE PREPARATION OF SULFAMOYLBENZOIC ACID DERIVATIVES | IAMA THERAPEUTICS S.R.L. (IT) | 2024-10-24 | — | — | WO | disclosed |
| CN-117143091-A | HBV core protein degradation agent based on hydrophobic tag technology and preparation method and application thereof | 山东大学 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-113801153-B | Benzenesulfonyl amine HBV capsid protein inhibitor containing boric acid and boric acid pinacol ester group, and preparation method and application thereof | 山东大学 | 2022-08-26 | — | — | CN | disclosed |
| US-20220184008-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION | ALMA MATER STUDIORUM - UNIVERSITA' DI BOLOGNA (IT) | 2022-06-16 | — | — | US | disclosed |
| US-5591754-A | Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | disclosed |
| CN-1137035-A | Basic group substituted benzoyl guanidine, its preparing process, its use as medicine or diagnostic reagent, and medicine containing the same | HOECHST AG (DE) | 1996-12-04 | — | — | CN | disclosed |
| EP-0723956-A1 | Basically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics as well as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-07-31 | — | — | EP | disclosed |
| EP-0416499-B1 | Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them | HOECHST AG (DE) | 1995-04-26 | — | — | EP | disclosed |
| EP-0589336-A1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-30 | — | — | EP | disclosed |
| US-5292755-A | USPA benzolyguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-08 | — | — | US | disclosed |
| US-5091394-A | BENZOYLGUANIDINES, A PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND MEDICAMENTS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
| CN-1050018-A | Benzoylguanidines, they the preparation method, they are as the application of medicament and the medicament that contains them | HOECHST AG (DE) | 1991-03-20 | — | — | CN | disclosed |
| EP-0416499-A2 | Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | PTK2B 1638/4885SMN1; SMN2 1694/4885CDC25B 192/4885 |
| US-20220184008-A1 | MODULATORS OF INTRACELLULAR CHLORIDE CONCENTRATION | SLC6A1, SLC6A13, SLC6A11 | PTK2B 2380/4885SMN1; SMN2 1048/4885CDC25B 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.